Vs Inverse VIX Short Term (XIV) 37.16

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vs Inverse VIX Short Term (XIV) 37.16 $XIV

VelocityShares Daily Inverse VIX ST ETN Has Returned 42.3% Since SmarTrend Recommendation (XIV)
Comtex SmarTrend(R) - Tue Aug 30, 12:42AM CDT
SmarTrend identified an Uptrend for VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) on July 7th, 2016 at $26.21. In approximately 2 months, VelocityShares Daily Inverse VIX ST ETN has returned 42.31% as of today's recent price of $37.30.
XIV: 37.16 (-0.28)

SmarTrend Watching for Potential Rebound in Shares of VelocityShares Daily Inverse VIX ST ETN After 1.44% Loss
Comtex SmarTrend(R) - Wed Aug 24, 11:52AM CDT
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $36.82 to a high of $37.47. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $36.86 on volume of 9.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XIV: 37.16 (-0.28)

Look for Shares of VelocityShares Daily Inverse VIX ST ETN to Potentially Pullback after Yesterday's 1.63% Rise
Comtex SmarTrend(R) - Mon Aug 15, 12:06PM CDT
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $37.27 to a high of $37.66. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $37.55 on volume of 8.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 37.16 (-0.28)

After Yesterday's Rally of 1.84% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 08, 11:55AM CDT
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $36.14 to a high of $36.60. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $36.28 on volume of 9.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 37.16 (-0.28)

Uptrend Call Working As VelocityShares Daily Inverse VIX ST ETN Stock Rises 31.9% (XIV)
Comtex SmarTrend(R) - Fri Aug 05, 1:06AM CDT
SmarTrend identified an Uptrend for VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) on July 7th, 2016 at $26.21. In approximately 4 weeks, VelocityShares Daily Inverse VIX ST ETN has returned 31.93% as of today's recent price of $34.58.
XIV: 37.16 (-0.28)

SmarTrend Watching for Potential Pullback in Shares of VelocityShares Daily Inverse VIX ST ETN After 3.36% Gain
Comtex SmarTrend(R) - Thu Aug 04, 11:50AM CDT
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $33.81 to a high of $34.90. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $34.67 on volume of 13.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 37.16 (-0.28)

VelocityShares Daily Inverse VIX ST ETN Set to Possibly Pullback After Yesterday's Rally of 2.56%
Comtex SmarTrend(R) - Fri Jul 29, 12:12PM CDT
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $32.46 to a high of $33.49. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $32.71 on volume of 12.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 37.16 (-0.28)

VelocityShares Daily Inverse VIX ST ETN Up 21.4% Since SmarTrend Uptrend Call (XIV)
Comtex SmarTrend(R) - Thu Jul 28, 1:56PM CDT
SmarTrend identified an Uptrend for VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) on July 7th, 2016 at $26.21. In approximately 3 weeks, VelocityShares Daily Inverse VIX ST ETN has returned 21.40% as of today's recent price of $31.82.
XIV: 37.16 (-0.28)

Watch for VelocityShares Daily Inverse VIX ST ETN to Potentially Pullback After Gaining 6.81% Yesterday
Comtex SmarTrend(R) - Thu Jun 23, 11:47AM CDT
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $28.47 to a high of $29.33. Yesterday, the shares gained 6.8%, which took the trading range above the 3-day high of $29.24 on volume of 14.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 37.16 (-0.28)

10 Highly Traded Leveraged/Inverse ETFs of 2Q
Sweta Killa - Zacks Investment Research - Wed Jun 22, 9:48AM CDT
We have profiled 10 leveraged/inverse ETFs that have seen massive trading volumes over the past 100 days.
TZA: 28.66 (+0.42), DGAZ: 6.59 (+0.47), TNA: 76.97 (-1.17), UVXY: 20.10 (+0.25), DUST: 38.40 (-3.81), UWTI: 19.31 (-2.18), NUGT: 19.37 (+1.58), TQQQ: 121.50 (-0.04), SVXY: 72.62 (-0.39), XIV: 37.16 (-0.28)

VelocityShares Daily Inverse VIX ST ETN Up 62.7% Since SmarTrend Uptrend Call (XIV)
Comtex SmarTrend(R) - Thu Jun 09, 12:43PM CDT
SmarTrend identified an Uptrend for VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) on March 1st, 2016 at $19.84. In approximately 3 months, VelocityShares Daily Inverse VIX ST ETN has returned 62.65% as of today's recent price of $32.28.
XIV: 37.16 (-0.28)

VelocityShares Daily Inverse VIX ST ETN Set to Possibly Pullback After Yesterday's Rally of 1.77%
Comtex SmarTrend(R) - Tue Jun 07, 12:02PM CDT
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $33.62 to a high of $34.10. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $33.58 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 37.16 (-0.28)

Shares of XIV Up 61.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 12:14AM CDT
SmarTrend identified an Uptrend for VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) on March 1st, 2016 at $19.84. In approximately 3 months, VelocityShares Daily Inverse VIX ST ETN has returned 61.00% as of today's recent price of $31.95.
XIV: 37.16 (-0.28)

VelocityShares Daily Inverse VIX ST ETN Rises 1.95% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri May 27, 11:51AM CDT
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $31.07 to a high of $31.45. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $31.12 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 37.16 (-0.28)

VelocityShares Daily Inverse VIX ST ETN Has Returned 54.7% Since SmarTrend Recommendation (XIV)
Comtex SmarTrend(R) - Wed May 25, 12:45PM CDT
SmarTrend identified an Uptrend for VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) on March 1st, 2016 at $19.84. In approximately 3 months, VelocityShares Daily Inverse VIX ST ETN has returned 54.70% as of today's recent price of $30.70.
XIV: 37.16 (-0.28)

SmarTrend Watching for Potential Rebound in Shares of VelocityShares Daily Inverse VIX ST ETN After 4.12% Loss
Comtex SmarTrend(R) - Thu May 19, 12:03PM CDT
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $26.23 to a high of $27.40. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $27.18 on volume of 22.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XIV: 37.16 (-0.28)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Flora Growth Corp Sees 6% Surge in After-Hours Performance

Updated Category News Views 87

A Surge in After-Hours Trading for Flora Growth Corp Flora Growth Corp. (NASDAQ: FLGC) recently demonstrated significant volatility by surging 5.98% to $10.55 during after-hours trading. This movement came not long after closing at $9.96, which marked an increase of 3.59% earlier that day. Insights from Recent SEC Filing Regulation A Filing In a notable move, Flora Growth...

Continue Reading
Qubs Introduces Qubitunes, A New Interactive Audio Experience

Updated Category News Views 205

Qubs Launches Qubitunes for Creative Play Qubs has unveiled an exciting new product, Qubitunes, which has already won the 'Top Toy' award in the startup category at a prestigious Toy Fair. This innovative toy is set to transform playtime for children by offering a unique platform where they can express their creativity and dive into their own audio storytelling...

Continue Reading
Asyad Group's Expert Transport of Heavy Cryogenic Tank

Updated Category News Views 126

Asyad Group's Successful Transport of Cryogenic Tank Asyad Group has recently completed a remarkable international transport operation, successfully moving a 115 metric ton pressurized cryogenic tank from Northern India to a major destination in Saudi Arabia. This endeavor highlights the Group's expertise in cross-border logistics. A Journey of Precision The transport...

Continue Reading
Famous Toastery Launches Holiday Fundraising Efforts

Updated Category News Views 134

Famous Toastery's Compassionate Campaign for Local Communities The Famous Toastery, known for its delightful breakfast and brunch offerings, is stepping up this holiday season with a noble initiative aimed at fighting hunger. This renowned franchise is collaborating with Feeding the Carolinas, encouraging guests to make donations that will significantly impact individuals...

Continue Reading
Jiayin Group's Upcoming Earnings Call Set for November 25, 2025

Updated Category News Views 190

Jiayin Group Inc. Announces Q3 2025 Financial Results Release Jiayin Group Inc. (NASDAQ: JFIN), a prominent fintech platform in China, has shared significant news that it will unveil its unaudited financial outcomes for the third quarter of 2025. This crucial announcement is set to occur before the U.S. markets open on November 25, 2025. The anticipation surrounding these...

Continue Reading